Atrophic gastritis is a basic precancerous disease of the stomach and serological markers have been demonstrated effective for screening for atrophic gastritis and, in turn, preventing gastric cancer. Recently, a clinical study involving 169 patients with atrophic gastritis evaluated the effectiveness of assessing postprandial levels of gastrin-17 (G17) for screening atrophic gastritis. In the study, the histological standard of 5 biopsies of the gastric mucosa was used to assess the sensitivity of G17 in detecting gastric mucosal atrophy. Also, the morpho-functional relationships between the detected histological degree of gastric mucosal atrophy and the serological levels of G17 and pepsinogen-1 (PG1) were compared. The sensitivity of postprandial G17 was 62.2% for serological levels of G17 and 100% for serological G17 for the detection of mono-focal severe atrophic gastritis⁴. Thus, postprandial G17 can be recommended for dynamic monitoring of atrophic gastritis after treatment.

References
4. Kotelevets et al. World J Gastrointest Endosc 2024; 16: 462–71.